136 lines
No EOL
17 KiB
XML
136 lines
No EOL
17 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548611" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548611/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Substance Abuse Treatment Agents - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Substance Abuse Treatment Agents" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2021/09/07" /><meta name="citation_pmid" content="31643923" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548611/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Substance Abuse Treatment Agents" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2021/09/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548611/" /><meta name="description" content="The Substance Abuse Treatment Agents are used in combination with structured relapse prevention interventions to treat alcohol, opiate, nicotine and other drug dependencies. These agents are usually not effective on their own and are considered adjunctive therapy to multidisciplinary substance abuse treatment." /><meta name="og:title" content="Substance Abuse Treatment Agents" /><meta name="og:type" content="book" /><meta name="og:description" content="The Substance Abuse Treatment Agents are used in combination with structured relapse prevention interventions to treat alcohol, opiate, nicotine and other drug dependencies. These agents are usually not effective on their own and are considered adjunctive therapy to multidisciplinary substance abuse treatment." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548611/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/SubstanceAbuseTreatm/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548611/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C8C547D7E9E4100000000013E00FC.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548611_"><span class="title" itemprop="name">Substance Abuse Treatment Agents</span></h1><p class="small">Last Update: <span itemprop="dateModified">September 7, 2021</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="SubstanceAbuseTreatm.OVERVIEW"><h2 id="_SubstanceAbuseTreatm_OVERVIEW_">OVERVIEW</h2><p>The Substance Abuse Treatment Agents are used in combination with structured relapse prevention interventions to treat alcohol, opiate, nicotine and other drug dependencies. These agents are usually not effective on their own and are considered adjunctive therapy to multidisciplinary substance abuse treatment.</p><p>The substance abuse treatment agents are generally classified based upon the specific dependency or abuse. Thus, drugs used for maintenance of alcohol withdrawal include disulfiram, acamprosate and naltrexone. Agents used for opiate withdrawal include buprenorphine, methadone and naltrexone. Agents for smoking cessation include nicotine and varenicline. The agents can also be classified as deterrents (disulfiram, naltrexone), neurotransmitter analogues (acamprosate, varenicline), and agents that block withdrawal symptoms (buprenorphine, methadone, nicotine). Disulfiram has been linked to many cases of acute liver injury, some of which are severe and even fatal. The other substance abuse treatment agents have little or no hepatoxic potential unless taken in an overdose (buprenorphine).</p><p>The Substance Abuse Treatment Agents in clinical use include the following:</p><ul><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Acamprosate/">Acamprosate</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Buprenorphine/">Buprenorphine</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Disulfiram/">Disulfiram</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Methadone/">Methadone</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Nalmefene/">Nalmefene</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Naloxegol/">Naloxegol</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Naloxone/">Naloxone</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Naltrexone/">Naltrexone</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Nicotine/">Nicotine</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="/books/n/livertox/Varenicline/">Varenicline</a>
|
||
</div></li></ul></div><div id="SubstanceAbuseTreatm.SELECTED_ANNOTATED"><h2 id="_SubstanceAbuseTreatm_SELECTED_ANNOTATED_">SELECTED ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 07 September 2021</p><ul class="first-line-outdent"><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.zimmerman.1999">Zimmerman HJ. Drugs used in aversion therapy. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 724-6.<div><i>(Expert review of hepatotoxicity published in 1999: discussion of hepatotoxicity of alcohol aversion pharmacotherapy is limited to disulfiram).</i></div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.zimmerman.1999_1">Zimmerman HJ. Narcotic analgesics. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 724-6.<div><i>(Expert review of hepatotoxicity published in 1999 includes discussion of hepatotoxicity of morphine, heroin, methadone, codeine and naltrexone).</i></div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.mihic.2018">Mihic SJ, Koob GF, Mayfield J, Harris RA. Ethanol. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 421-31.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF4">O’Brien. Drug use disorders and addiction. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 433-42.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.mattick.2003.441">Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <span><span class="ref-journal">Addiction. </span>2003;<span class="ref-vol">98</span>:441–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12653814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12653814</span></a>]<div>
|
||
<i>(Controlled trial in 405 patients with opioid dependence found similar rates of adverse events with buprenorphine and methadone; one patient had hepatitis C, but no other liver related adverse events reported).</i>
|
||
</div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.fudala.2003.949">Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, et al. Buprenorphine/ Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>:949–58.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12954743" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12954743</span></a>]<div>
|
||
<i>(Controlled trial of buprenorphine/naloxone vs buprenorphine alone vs placebo for 4 weeks in 326 opiate addicted patients; ALT elevations occurred in 10 patients, but 8 had concurrent hepatitis B or C).</i>
|
||
</div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF7">Drugs for smoking cessation. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2019;<span class="ref-vol">61</span>(1576):105–10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31381546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31381546</span></a>]<div>
|
||
<i>(Concise review of the mechanisms of action, clinical efficacy, safety and costs of drugs for smoking cessation mentions that side effects of varenicline include nausea and constipation, dizziness and headache and sleep disturbances with insomnia and vivid dreams; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="SubstanceAbuseTreatm.REF.goh.2017.865">Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore. <span><span class="ref-journal">Aliment Pharmacol Ther. </span>2017;<span class="ref-vol">45</span>:865–882.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28220511" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28220511</span></a>]<div>
|
||
<i>(Review of medical therapies for alcohol dependence including disulfiram, a well known cause of acute liver injury, and acamprosate which is not metabolized in the liver, has not been implicated in cases of liver injury, and is generally safe even in persons with impaired hepatic function).</i>
|
||
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548611</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643923" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643923</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Streptozocin/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Succimer/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548611&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548611/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |